Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 76.2% in June

Dyadic International Inc. (NASDAQ:DYAI) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 148,312 shares, a drop of 76.2% from the May 31st total of 622,465 shares. Based on an average trading volume of 188,919 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.5% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On Dyadic International

Large investors have recently modified their holdings of the business. Bank of America Corp DE increased its position in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Marathon Capital Management acquired a new position in Dyadic International in the third quarter valued at about $41,000. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the third quarter valued at about $190,000. Geode Capital Management LLC boosted its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Finally, Apis Capital Advisors LLC purchased a new position in Dyadic International during the third quarter worth about $1,817,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Trading Up 8.1%

Shares of NASDAQ DYAI traded up $0.06 during midday trading on Friday, reaching $0.80. 394,340 shares of the stock were exchanged, compared to its average volume of 211,907. The company has a 50 day simple moving average of $0.76 and a 200 day simple moving average of $0.83. The stock has a market capitalization of $29.19 million, a P/E ratio of -3.48 and a beta of 1.17. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International has a twelve month low of $0.65 and a twelve month high of $1.35.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, equities analysts expect that Dyadic International will post 0.13 earnings per share for the current year.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.